HUE036600T2 - ERK inhibitorok és alkalmazási eljárások - Google Patents
ERK inhibitorok és alkalmazási eljárásokInfo
- Publication number
- HUE036600T2 HUE036600T2 HUE14850964A HUE14850964A HUE036600T2 HU E036600 T2 HUE036600 T2 HU E036600T2 HU E14850964 A HUE14850964 A HU E14850964A HU E14850964 A HUE14850964 A HU E14850964A HU E036600 T2 HUE036600 T2 HU E036600T2
- Authority
- HU
- Hungary
- Prior art keywords
- erk
- inhibitors
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361886552P | 2013-10-03 | 2013-10-03 | |
| US201462032446P | 2014-08-01 | 2014-08-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE036600T2 true HUE036600T2 (hu) | 2018-07-30 |
Family
ID=52779215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE14850964A HUE036600T2 (hu) | 2013-10-03 | 2014-10-03 | ERK inhibitorok és alkalmazási eljárások |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US9624228B2 (hu) |
| EP (2) | EP3052096B8 (hu) |
| JP (2) | JP6427197B2 (hu) |
| KR (1) | KR20160081908A (hu) |
| CN (2) | CN108864102A (hu) |
| AU (2) | AU2014331628B2 (hu) |
| BR (1) | BR112016006994A8 (hu) |
| CA (1) | CA2924584A1 (hu) |
| CY (1) | CY1120095T1 (hu) |
| DK (1) | DK3052096T3 (hu) |
| EA (1) | EA032196B1 (hu) |
| ES (1) | ES2664794T3 (hu) |
| HK (1) | HK1255851A1 (hu) |
| HR (1) | HRP20180538T1 (hu) |
| HU (1) | HUE036600T2 (hu) |
| IL (1) | IL244488A0 (hu) |
| LT (1) | LT3052096T (hu) |
| ME (1) | ME02991B (hu) |
| MX (1) | MX2016004163A (hu) |
| PH (1) | PH12016500432B1 (hu) |
| PL (1) | PL3052096T3 (hu) |
| PT (1) | PT3052096T (hu) |
| RS (1) | RS57058B1 (hu) |
| SG (1) | SG11201602572YA (hu) |
| SI (1) | SI3052096T1 (hu) |
| WO (1) | WO2015051341A1 (hu) |
| ZA (1) | ZA201601701B (hu) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE036600T2 (hu) | 2013-10-03 | 2018-07-30 | Kura Oncology Inc | ERK inhibitorok és alkalmazási eljárások |
| CN109661228A (zh) * | 2016-06-20 | 2019-04-19 | 库拉肿瘤学公司 | 用erk抑制剂治疗鳞状细胞癌 |
| BR112019020277B1 (pt) | 2017-03-28 | 2023-02-14 | Basf Se | Compostos, composição, método para combater ou controlar pragas de invertebrados, método para proteger plantas em crescimento, semente tratada, usos de um composto da fórmula i |
| WO2019076336A1 (zh) * | 2017-10-19 | 2019-04-25 | 江苏豪森药业集团有限公司 | 含吡唑基的三并环类衍生物、其制备方法和应用 |
| CN109761986B (zh) * | 2017-11-10 | 2021-10-08 | 上海翰森生物医药科技有限公司 | 三并环类衍生物抑制剂、其制备方法和应用 |
| CN107879989B (zh) * | 2017-11-29 | 2020-01-03 | 重庆市中药研究院 | 具有生物活性的3,4,5-取代苯并二氮卓2-酮类药物分子及其制备方法 |
| EP3643705A1 (en) | 2018-10-24 | 2020-04-29 | Basf Se | Pesticidal compounds |
| SG11202104404XA (en) * | 2018-11-16 | 2021-05-28 | California Inst Of Techn | Erk inhibitors and uses thereof |
| WO2020200161A1 (zh) * | 2019-04-02 | 2020-10-08 | 上海翰森生物医药科技有限公司 | 含吲唑基的三并环类衍生物的盐及其晶型 |
| EP3766879A1 (en) | 2019-07-19 | 2021-01-20 | Basf Se | Pesticidal pyrazole derivatives |
| EP4198023A1 (en) | 2021-12-16 | 2023-06-21 | Basf Se | Pesticidally active thiosemicarbazone compounds |
| WO2023156402A1 (en) | 2022-02-17 | 2023-08-24 | Basf Se | Pesticidally active thiosemicarbazone compounds |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3657744A (en) | 1970-05-08 | 1972-04-25 | Univ Minnesota | Method for fixing prosthetic implants in a living body |
| BE791816R (fr) | 1971-11-24 | 1973-05-23 | Sandoz Sa | Derives de la quinazolinone, leur preparation et medicaments contenant ces |
| US3984556A (en) * | 1973-01-19 | 1976-10-05 | Sandoz, Inc. | Alkyl-substituted-tricyclic quinazolinones for lowering blood pressure |
| US4042704A (en) * | 1976-03-18 | 1977-08-16 | Sandoz, Inc. | Benzindazoles |
| US4352931A (en) | 1980-05-22 | 1982-10-05 | Siegfried Aktiengesellschaft | Lin-benzoaminopurinols |
| US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5350395A (en) | 1986-04-15 | 1994-09-27 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
| US5040548A (en) | 1989-06-01 | 1991-08-20 | Yock Paul G | Angioplasty mehtod |
| US5061273A (en) | 1989-06-01 | 1991-10-29 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
| US4748982A (en) | 1987-01-06 | 1988-06-07 | Advanced Cardiovascular Systems, Inc. | Reinforced balloon dilatation catheter with slitted exchange sleeve and method |
| DE3701277A1 (de) * | 1987-01-17 | 1988-07-28 | Boehringer Mannheim Gmbh | Neue tricyclische benzimidazole, verfahren zu ihrer herstellung und verwendung als arzneimittel |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| CA1322628C (en) | 1988-10-04 | 1993-10-05 | Richard A. Schatz | Expandable intraluminal graft |
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| US5292331A (en) | 1989-08-24 | 1994-03-08 | Applied Vascular Engineering, Inc. | Endovascular support device |
| US5674278A (en) | 1989-08-24 | 1997-10-07 | Arterial Vascular Engineering, Inc. | Endovascular support device |
| US6344053B1 (en) | 1993-12-22 | 2002-02-05 | Medtronic Ave, Inc. | Endovascular support device and method |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| IL112248A0 (en) * | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| EP0821671B1 (en) | 1995-04-20 | 2000-12-27 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors |
| DK0780386T3 (da) | 1995-12-20 | 2003-02-03 | Hoffmann La Roche | Matrixmetalloproteaseinhibitorer |
| EP0923585B1 (en) | 1996-07-18 | 2002-05-08 | Pfizer Inc. | Phosphinate based inhibitors of matrix metalloproteases |
| JP2000501423A (ja) | 1996-08-23 | 2000-02-08 | ファイザー インク． | アリールスルホニルアミノヒドロキサム酸誘導体 |
| PT950059E (pt) | 1997-01-06 | 2004-10-29 | Pfizer | Derivados de sulfona ciclicos |
| ID22799A (id) | 1997-02-03 | 1999-12-09 | Pfizer Prod Inc | Turunan-turunan asam arilsulfonilamino hidroksamat |
| JP2000507975A (ja) | 1997-02-07 | 2000-06-27 | ファイザー・インク | Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用 |
| IL131123A0 (en) | 1997-02-11 | 2001-01-28 | Pfizer | Arylsulfonyl hydroxamic acid derivatives |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| US6087368A (en) | 1998-06-08 | 2000-07-11 | Bristol-Myers Squibb Company | Quinazolinone inhibitors of cGMP phosphodiesterase |
| US6562836B1 (en) * | 1999-05-24 | 2003-05-13 | Queen's University Of Kingston | Methods and compounds for inhibiting amyloid deposits |
| DE60128709T2 (de) | 2000-09-15 | 2007-12-27 | Vertex Pharmaceuticals Inc., Cambridge | Triazol-verbindungen als protein-kinase-inhibitoren |
| JP3896309B2 (ja) * | 2001-07-09 | 2007-03-22 | ファイザー株式会社 | プロテインキナーゼｃ阻害物質としてのピラゾロキノリノン誘導体 |
| US7119111B2 (en) | 2002-05-29 | 2006-10-10 | Amgen, Inc. | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use |
| TWI339206B (en) | 2003-09-04 | 2011-03-21 | Vertex Pharma | Compositions useful as inhibitors of protein kinases |
| WO2005025515A2 (en) * | 2003-09-12 | 2005-03-24 | California Institute Of Technology | Proteasome pathway inhibitors and related methods |
| US7244757B2 (en) | 2004-04-01 | 2007-07-17 | Pfizer Inc | Pyrazole-amine compounds for the treatment of neurodegenerative disorders |
| US7384930B2 (en) | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
| US7807672B2 (en) | 2006-02-16 | 2010-10-05 | Schering Corporation | Compounds that are ERK inhibitors |
| NZ581698A (en) | 2007-06-05 | 2012-09-28 | Merck Sharp & Dohme | Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer |
| MX2009014208A (es) * | 2007-06-18 | 2010-01-28 | Schering Corp | Compuestos heterociclicos y usos de los mismos como inhibidores de erk. |
| WO2010107742A2 (en) | 2009-03-18 | 2010-09-23 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions of treating a flaviviridae family viral infection |
| WO2009046025A1 (en) | 2007-10-01 | 2009-04-09 | Comentis, Inc. | Quinuclidin-4-ylmethyl 1h-indole-3-carboxylate derivatives as alpha 7 nicotinic acetylcholine receptor ligands for the treatment of alzheimer's disease |
| ES2556353T3 (es) | 2008-02-21 | 2016-01-15 | Merck Sharp & Dohme Corp. | Compuestos que son inhibidores de las ERK |
| US8022227B2 (en) * | 2008-08-27 | 2011-09-20 | The Ohio State University | Method of synthesizing 1H-indazole compounds |
| EP2746282A1 (en) * | 2009-07-17 | 2014-06-25 | Japan Tobacco Inc. | Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer |
| AU2010300925A1 (en) | 2009-09-30 | 2012-03-29 | Merck Sharp & Dohme Corp. | Novel compounds that are ERK inhibitors |
| EP2613782B1 (en) | 2010-09-01 | 2016-11-02 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
| US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
| EP3536319A1 (en) | 2010-10-29 | 2019-09-11 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| WO2012170845A2 (en) * | 2011-06-08 | 2012-12-13 | Heffernan Michele L R | Metabotropic glutamate receptor 5 modulators and methods of use thereof |
| EP2770987B1 (en) | 2011-10-27 | 2018-04-04 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| MX2015004041A (es) | 2012-09-28 | 2015-07-06 | Merck Sharp & Dohme | Compuestos novedosos que son inhibidores de erk. |
| US9226922B2 (en) | 2012-09-28 | 2016-01-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
| WO2014134772A1 (en) | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| US9745307B2 (en) | 2013-04-30 | 2017-08-29 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
| HUE036600T2 (hu) | 2013-10-03 | 2018-07-30 | Kura Oncology Inc | ERK inhibitorok és alkalmazási eljárások |
| WO2016095089A1 (en) | 2014-12-15 | 2016-06-23 | Merck Sharp & Dohme Corp. | Erk inhibitors |
| WO2016095088A1 (en) | 2014-12-15 | 2016-06-23 | Merck Sharp & Dohme Corp. | Erk inhibitors |
| EP3233824B1 (en) | 2014-12-18 | 2021-12-01 | Merck Sharp & Dohme Corp. | (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3- (methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations |
| MX2017008078A (es) | 2014-12-19 | 2017-09-28 | Merck Sharp & Dohme | Composiciones de (s)-n-(3-(6-isopropoxipiridin-3-il)-1h-indazol-5- il)-1-(2-(4-(4-(1-metil-1h-1,2,4-triazol-3-il)fenil)-3,6-dihidrop iridin-1(2h)-il)-2-oxoetil)-3-(metiltio)pirrolidin-3-carboxamida para preparaciones farmaceuticas. |
| TWI704151B (zh) | 2014-12-22 | 2020-09-11 | 美商美國禮來大藥廠 | Ｅｒｋ抑制劑 |
-
2014
- 2014-10-03 HU HUE14850964A patent/HUE036600T2/hu unknown
- 2014-10-03 US US15/026,581 patent/US9624228B2/en not_active Expired - Fee Related
- 2014-10-03 LT LTEP14850964.9T patent/LT3052096T/lt unknown
- 2014-10-03 EP EP14850964.9A patent/EP3052096B8/en active Active
- 2014-10-03 EA EA201690708A patent/EA032196B1/ru not_active IP Right Cessation
- 2014-10-03 CN CN201810401122.XA patent/CN108864102A/zh active Pending
- 2014-10-03 SI SI201430659T patent/SI3052096T1/en unknown
- 2014-10-03 ES ES14850964.9T patent/ES2664794T3/es active Active
- 2014-10-03 PL PL14850964T patent/PL3052096T3/pl unknown
- 2014-10-03 BR BR112016006994A patent/BR112016006994A8/pt not_active Application Discontinuation
- 2014-10-03 MX MX2016004163A patent/MX2016004163A/es unknown
- 2014-10-03 EP EP17204999.1A patent/EP3363800A1/en not_active Withdrawn
- 2014-10-03 JP JP2016546894A patent/JP6427197B2/ja not_active Expired - Fee Related
- 2014-10-03 CN CN201480054909.3A patent/CN105636586B/zh not_active Expired - Fee Related
- 2014-10-03 CA CA2924584A patent/CA2924584A1/en not_active Abandoned
- 2014-10-03 DK DK14850964.9T patent/DK3052096T3/en active
- 2014-10-03 KR KR1020167011270A patent/KR20160081908A/ko not_active Application Discontinuation
- 2014-10-03 PT PT148509649T patent/PT3052096T/pt unknown
- 2014-10-03 SG SG11201602572YA patent/SG11201602572YA/en unknown
- 2014-10-03 WO PCT/US2014/059197 patent/WO2015051341A1/en active Application Filing
- 2014-10-03 RS RS20180373A patent/RS57058B1/sr unknown
- 2014-10-03 ME MEP-2018-90A patent/ME02991B/me unknown
- 2014-10-03 AU AU2014331628A patent/AU2014331628B2/en not_active Ceased
-
2016
- 2016-03-07 PH PH12016500432A patent/PH12016500432B1/en unknown
- 2016-03-08 IL IL244488A patent/IL244488A0/en unknown
- 2016-03-11 ZA ZA2016/01701A patent/ZA201601701B/en unknown
-
2017
- 2017-02-22 US US15/439,719 patent/US9951078B2/en not_active Expired - Fee Related
-
2018
- 2018-02-14 US US15/896,929 patent/US10301317B2/en not_active Expired - Fee Related
- 2018-03-27 CY CY20181100340T patent/CY1120095T1/el unknown
- 2018-04-04 HR HRP20180538TT patent/HRP20180538T1/hr unknown
- 2018-10-18 AU AU2018250439A patent/AU2018250439A1/en not_active Abandoned
- 2018-10-26 JP JP2018201905A patent/JP2019031549A/ja active Pending
- 2018-11-22 HK HK18114927.9A patent/HK1255851A1/zh unknown
-
2019
- 2019-03-29 US US16/370,718 patent/US20190292194A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1217410A1 (zh) | 抑制劑及其用途 | |
| HK1224140A1 (zh) | 轉錄因子抑制劑及其用途 | |
| HK1255851A1 (zh) | Erk的雜環抑制劑及其使用方法 | |
| EP2964651A4 (en) | BMP HEMMER AND METHOD OF USE THEREOF | |
| EP2970311A4 (en) | BMP INHIBITORS AND METHODS OF USE | |
| SG11201504022RA (en) | Glutamase inhibitors and method of use | |
| EP2975938A4 (en) | Inhibitors of prmt5 and methods of their use | |
| HRP20181291T1 (hr) | Heterobicikloarilni inhibitori rorc2 i njihova upotreba | |
| SI2909204T1 (sl) | Inhibitorji GSK3 in postopki njihove uporabe | |
| HK1207968A1 (en) | Usp30 inhibitors and methods of use usp30 | |
| HK1224307A1 (zh) | 原毒素- 變體及其使用方法 | |
| IL245272A0 (en) | pif-transfected cells and methods of use | |
| IL240695A0 (en) | nme inhibitors and methods of using nme inhibitors | |
| PT3024825T (pt) | Imidazolecarboxamidas e seu uso como inibidores da faah | |
| EP3073825A4 (en) | Inhibitors of ercc1-xpf and methods of using the same |